O uso dos inibidores da Dipeptidil Peptidase tipo 4 na preservação de células β pancreática através da dosagem de peptídeo C em pacientes com diabetes autoimune latente do adulto

Autores

DOI:

10.24281/rremecs2024.9.15.138146

Palavras-chave:

LADA, Peptídeo C, Insulina, Inibidores da Dipeptidil Peptidase Tipo 4

Resumo

O diabetes autoimune latente do adulto (LADA) é uma condição que combina características do Diabetes Tipo 1 e Tipo 2, afetando 2% a 12% dos pacientes com diabetes. O diagnóstico é baseado no início em idade adulta, presença de autoanticorpos das ilhotas e independência da insulina. A terapia com insulina é essencial quando o peptídeo C é indetectável, mas o LADA geralmente tem uma progressão mais lenta para a dependência de insulina. Estudos estão investigando o uso de inibidores da dipeptidil peptidase tipo 4 (I-DPP4) para controlar a glicemia e preservar as células β em pacientes com LADA. Uma revisão de estudos identificou potencial promissor desses medicamentos na preservação das células β pancreáticas, incluindo aumento do peptídeo C basal com Linagliptina e manutenção dos níveis com Sitagliptina, especialmente quando combinada com outras terapias. No entanto, são necessários mais estudos para confirmar esses achados e entender melhor seu papel no tratamento do LADA.
Descritores: LADA, Peptídeo C, Insulina, Inibidores da Dipeptidil Peptidase Tipo 4.

 

The use of dipeptidyl peptidase type 4 inhibitors in the preservation of pancreatic β cells through C-peptide measurement in patients with latent autoimmune diabetes in adults: a systematic review

Abstract: Latent autoimmune diabetes of adults (LADA) is a condition that combines features of Type 1 and Type 2 Diabetes, affecting 2% to 12% of patients with diabetes. Diagnosis is based on adult onset, presence of islet autoantibodies, and insulin independence. Insulin therapy is essential when C-peptide is undetectable, but LADA generally has a slower progression to insulin dependence. Studies are investigating the use of dipeptidyl peptidase type 4 (I-DPP4) inhibitors to control glycemia and preserve β-cells in patients with LADA. A review of studies identified promising potential of these medications in preserving pancreatic β cells, including increasing basal C-peptide with Linagliptin and maintaining levels with Sitagliptin, especially when combined with other therapies. However, more studies are needed to confirm these findings and better understand its role in the treatment of LADA.
Descriptors: LADA, C-peptide, Insulin, Type 4 Dipeptidyl Peptidase Inhibitors.

 

El uso de inhibidores de la dipeptidil peptidasa tipo 4 en la preservación de las células β pancreáticas mediante la dosificación de péptido C en pacientes con diabetes autoinmune latente en adultos: revisión sistemática

Resumen: La diabetes autoinmune latente en adultos (LADA) es una afección que combina características de la diabetes tipo 1 y tipo 2 y afecta entre el 2% y el 12% de los pacientes con diabetes. El diagnóstico se basa en el inicio en la edad adulta, la presencia de autoanticuerpos de los islotes y la independencia de la insulina. La terapia con insulina es esencial cuando el péptido C es indetectable, pero LADA generalmente tiene una progresión más lenta hacia la dependencia de insulina. Los estudios están investigando el uso de inhibidores de la dipeptidil peptidasa tipo 4 (I-DPP4) para controlar la glucemia y preservar las células β en pacientes con LADA. Una revisión de los estudios identificó el potencial prometedor de estos medicamentos para preservar las células β pancreáticas, incluido el aumento del péptido C basal con linagliptina y el mantenimiento de los niveles con sitagliptina, especialmente cuando se combinan con otras terapias. Sin embargo, se necesitan más estudios para confirmar estos hallazgos y comprender mejor su papel en el tratamiento de LADA.
Descriptores: LADA, Péptido C, Insulina, Inhibidores de Dipeptidil Peptidasa Tipo 4.

Referências

Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. United Kingdom Prospective Diabetes Study Group. London, England: Lancet. 1997; 350(9087):1288-93.

Liu B, Xiang Y, Liu Z, Zhou Z. Past, Present, and Future of Latent Autoimmune Diabetes in Adults. Diabetes/Metabolism Res Rev. 2020; 36(1):e3205.

Leslie RD, Pozzilli P. Type I Diabetes Masquerading as Type II Diabetes: Possible Implications for Prevention and Treatment. Diabetes Care. 1994; 17(10):1214-9.

Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with non-insulin-dependent onset of disease. Diabetes. 1993; 42(2):359-62.

Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international panel of experts. Diabetes. 2020; 69(10):2037-47.

Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005; 48:2206-2212.

Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab. 2009; 94:4635-4644.

Brophy S, Yderstraede K, Mauricio D, Hunter S, Hawa M, Pozzilli P, et al. Time to insulin initiation cannot be used in the definition of latent autoimmune diabetes in adults. Diabetes Care. 2008; 31:439-441.

Takeda H, Kawasaki E, Shimizu I, Konoue E, Fujiyama M, Murao S, et al. Clinical, autoimmune, and genetic characteristics of japanese adult diabetic patients with GAD autoantibodies (Ehime Study). Diabetes Care. 2002; 25:995-1001.

Rasouli B, Andersson T, Carlsson PO, Grill V, Groop L, Martinell M, et al. Smoking and the risk of LADA: results from a population-based case-control study in sweden. Diabetes Care. 2016; 39:794-800.

Hawa MI, Kolb H, Schloot N, et al. Action LADA consortium. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care 2013; 36:908-913.

Hernandez M, Mollo A, Marsal JR, et al. Action LADA consortium. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9. BMC Endocr Disord 2015; 15:1.

Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45:622-626.

Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol (Lausanne). 2019; 10:389.

Johansen OE, Boehm BO, Grill V, Torjesen PA, Bhattacharya S, Patel S, et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care. 2014; 37(1):e11-2.

Zhao Y, Yang L, Xiang Y, Liu L, Huang G, Long Z, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab. 2014; 99(5):E876-80.

Hals IK, Fiskvik Fleiner H, Reimers N, Astor MC, Filipsson K, Ma Z, et al. Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: results from a 21-month randomized trial. Diabetes Obes Metab. 2019; 21(10):2219-2227.

Zhang Z, Yan X, Wu C, Pei X, Li X, Wang X, et al. Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study.Diabetes Metab Res Rev. 2020 Jul;36(5):e3298.

Yang L, Liang H, Liu X, Wang X, Cheng Y, Zhao Y, et al. Islet function and insulin sensitivity in latent autoimmune diabetes in adults taking sitagliptin: a randomized trial. J Clin Endocrinol Metab. 2021; 106(4):e1529-e1541.

Takahashi A, Nagashima K, Hamasaki A, Kuwamura N, Kawasaki Y, Ikeda H, et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract. 2007; 77(3):343-50.

Pinheiro MM, Pinheiro FMM, Diniz SN, Fabbri A, Infante M. Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes. Int Immunopharmacol. 2021; 95:107518.

Duvnjak L, Blaslov K, Vučić Lovrenčić M, Knežević Ćuća J. Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes. Diabetes Res Clin Pract. 2016; 121:119-126.

Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. J Endocrinol. 2012; 214(3):381-7.

Kim SJ, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV inhibition with MK0431 improve islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes. 2009; 58(3):641-51.

Kim S, Nian C, McIntosh CHS. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and independent pathways. Diabetes 2010; 59(7):1739-50.

Alonso N, Julián MT, Carrascal J, Colobran R, Pujol-Autonell I, Rodriguez-Fernández S, et al. Type 1 diabetes prevention in NOD mice by targeting DPPIV/CD26 is associated with changes in CD8⁺T effector memory subset. PLoS One 2015; 10(11):e0142186.

Pinheiro MM, Stoppa CL, Valduga CJ, Okuyama CE, Gorjão R, Pereira RM, et al. Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro. Eur J Pharm Sci 2017; 100:17-24.

Publicado

09-08-2024
Métricas
  • Visualizações 0
  • pdf downloads: 0

Como Citar

MALUF, J. F. M. .; GUIMARÃES, M. F. .; CALESTINI, G. L. da S. O uso dos inibidores da Dipeptidil Peptidase tipo 4 na preservação de células β pancreática através da dosagem de peptídeo C em pacientes com diabetes autoimune latente do adulto. Revista Remecs - Revista Multidisciplinar de Estudos Cientí­ficos em Saúde, [S. l.], v. 9, n. 15, p. 138–146, 2024. DOI: 10.24281/rremecs2024.9.15.138146. Disponível em: https://www.revistaremecs.com.br/index.php/remecs/article/view/1679. Acesso em: 11 dez. 2024.